Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome

Blood (2018) 132 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2018-99-118123

Published: 2018

Journal Articles

High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry

Blood (2012) 120 (21): 1702.

https://doi.org/10.1182/blood.V120.21.1702.1702

Published: 2012

Journal Articles

Assessment of Frailty Measures and Their Effect on Survival in a Population of Patients Registered At Marche Region Multiple Myeloma (MM) Registry

Massimo Offidani, MD, Claudia Polloni, Laura Corvatta, Riccardo Centurioni, MD, Giuseppe Visani, Marino Brunori, Silvia Gentili, Massimo Catarini, Arduino Samori, Nicola Blasi, Francesco Alesiani, Patrizia Caraffa, Maurizio Burattini, Piero Galieni, Paolo Fraticelli, Mario Ferranti, Luciano Giuliodori, Pietro Leoni

Blood (2011) 118 (21): 2873.

https://doi.org/10.1182/blood.V118.21.2873.2873

Published: 2011

Journal Articles

Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat In Patients with Relapsed/Refractory MM: a Phase I-II Study

Massimo Offidani, MD, Federica Cavallo, Claudia Polloni, Anna Marina Liberati, Stelvio Ballanti, Stefano Pulini, Massimo Catarini, Francesco Alesiani, Laura Corvatta, Silvia Gentili, Mario Boccadoro, Pietro Leoni, MD, Antonio Palumbo

Blood (2010) 116 (21): 3019.

https://doi.org/10.1182/blood.V116.21.3019.3019

Published: 2010

Journal Articles

Thalidomide, Dexamethasone, Doxil and Velcade (ThaDD-V) Induction Therapy Followed by Consolidation/Maintenance Is Very Effective In Early Relapsed/Refractory MM

Massimo Offidani, Claudia Polloni, Laura Corvatta, Silvia Gentili, Anna Mele, Marino Brunori, Rita Rizzi, Massimo Catarini, Arduino Samori, Nicola Blasi, Mario Ferranti, Lara Malerba, Patrizia Caraffa, Pietro Leoni

Blood (2010) 116 (21): 3020.

https://doi.org/10.1182/blood.V116.21.3020.3020

Published: 2010

Journal Articles

MPT Vs ThaDD in Very Elderly Patients with Multiple Myeloma: a Case-Match Study.

Blood (2009) 114 (22): 1835.

https://doi.org/10.1182/blood.V114.22.1835.1835

Published: 2009

Journal Articles

Multicentric prospective Study of Differential Treatment for Elderly Patients Affected by Aggressive Non Hodgkin Lymphoma Based On a Geriatric Multidimensional Analysis.

Guido Gini, Attilio Olivieri, MD, Caterina Bocci, Massimo Catarini, Giuseppe Visani, Mauro Montanari, M.D., Barbara Guiducci, Alessandro Isidori, MD, PhD, Marino Brunori, Francesco Alesiani, Luciano Giuliodori, Massimo Marcellini, Massimo Offidani, MD, Patrizia Caraffa, Andrea Stronati, Debora Capelli, Silvia Trappolini, Pietro Leoni

Blood (2009) 114 (22): 4775.

https://doi.org/10.1182/blood.V114.22.4775.4775

Published: 2009

Journal Articles

Infection Complications in Patients with Multiple Myeloma Treated with New-Drug Combinations Including Thalidomide.

Blood (2009) 114 (22): 2828.

https://doi.org/10.1182/blood.V114.22.2828.2828

Published: 2009

Journal Articles

ThaDD Regimen for Patients with Multiple Myeloma Aged ≥ 65 Years: An Update of the First 50 Patients Enrolled

Blood (2008) 112 (11): 5186.

https://doi.org/10.1182/blood.V112.11.5186.5186

Published: 2008

Journal Articles

Role of Previous Thalidomide Administration on Final Outcome for 72 Patients with Relapsed Multiple Myeloma (MM) Treated with Bortezomib–Based Therapy

Massimo Offidani, MD, Laura Corvatta, Claudia Polloni, Maria-Novella Piersantelli, Silvia Gentili, Miriana Ruggieri, Lara Malerba, Francesco Alesiani, Massimo Catarini, Marino Brunori, Arduino Samori, Maurizio Burattini, Luisa Minnucci, Anna Mele, Monica Marconi, Pietro Leoni

Blood (2008) 112 (11): 5191.

https://doi.org/10.1182/blood.V112.11.5191.5191

Published: 2008

Journal Articles

Safety and Efficacy of ThaDD Regimen in Very Elderly Patients with Multiple Myeloma (MM)

Massimo Offidani, MD, Laura Corvatta, Maria-Novella Piersantelli, Claudia Polloni, Silvia Gentili, Piero Galieni, Giuseppe Visani, Francesco Alesiani, Massimo Catarini, Marino Brunori, Arduino Samori, Maurizio Burattini, Riccardo Centurioni, Mario Ferranti, Luciano Giuliodori, Marco Candela, Monica Marconi, Anna Mele, Pietro Leoni

Blood (2008) 112 (11): 5196.

https://doi.org/10.1182/blood.V112.11.5196.5196

Published: 2008

Journal Articles

R-COMP 21 (Prednisone, Cyclophosphamide, Vincristine, Myocet tm and Rituximab) for Frail and Elderly Patients with Aggressive B-Cell Non-Hodgkin Lymphoma: A Pilot Study.

Alessandro Isidori, MD, Felicetto Ferrara, MD, Francesco Alesiani, MD, Sonia Ronconi, MD, Massimo Catarini, MD, Francesca D’Adamo, MD, Barbara Guiducci, MD, Daniele Bernardi, MD, Giuseppe Visani, MD

Blood (2007) 110 (11): 4442.

https://doi.org/10.1182/blood.V110.11.4442.4442

Published: 2007

Journal Articles

ThaDD-V Treatment for Patients with Relapsed/Refractory Multiple Myeloma: A Feasibility/Activity Study.

Massimo Offidani, MD, Claudia Polloni, MD, Laura Corvatta, MD, Maria-Novella Piersantelli, MD, Anna Mele, MD, Massimo Catarini, MD, Marino Brunori, MD, Mario Ferranti, MD, Barbara Amoroso, MD, Pietro Leoni, PhD

Blood (2007) 110 (11): 2729.

https://doi.org/10.1182/blood.V110.11.2729.2729

Published: 2007

Journal Articles

Thalidomide-Dexamethasone vs Interferon-α-Dexamethasone as Maintenance Treatment after ThaDD Induction for Multiple Myeloma (MM): Final Analysis of a Prospective, Randomized Study.

Massimo Offidani, MD, Claudia Polloni, MD, Laura Corvatta, MD, Maria-Novella Piersantelli, MD, Piero Galieni, MD, Giuseppe Visani, MD, Francesco Alesiani, MD, Massimo Catarini, MD, Marino Brunori, MD, Maurizio Burattini, MD, Riccardo Centurioni, MD, Mario Ferranti, MD, Luciano Giuliodori, MD, Marco Candela, MD, Anna Mele, MD, Monica Marconi, MD, Pietro Leoni, PhD

Blood (2007) 110 (11): 532.

https://doi.org/10.1182/blood.V110.11.532.532

Published: 2007

Journal Articles

Thalidomide-Dexamethasone (Thal-dex) vs Interferon-α-Dexamethasone (IFN-dex) as Maintenance Treatment after ThaDD Induction for Multiple Myeloma (MM): First Analysis of a Prospective Randomized Study.

Massimo Offidani, MD, Laura Corvatta, MD, Claudia Polloni, MD, Maria-Novella Piersantelli, MD, Piero Galieni, MD, Giuseppe Visani, MD, Francesco Alesiani, MD, Massimo Catarini, MD, Marino Brunori, MD, Maurizio Burattini, MD, Riccardo Centurioni, MD, Mario Ferranti, MD, Luciano Giuliodori, MD, Marco Candela, MD, Monica Marconi, MD, Pietro Leoni, PhD

Blood (2006) 108 (11): 3566.

https://doi.org/10.1182/blood.V108.11.3566.3566

Published: 2006

Journal Articles

Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma

Blood (2006) 108 (7): 2159–2164.

https://doi.org/10.1182/blood-2006-03-013086

Published: 2006

Journal Articles

Thalidomide, Dexamethasone and Pegylated-Liposomal Doxorubicin (ThaDD) for Untreated Multiple Myeloma Patients Aged over 65 Years.

Massimo Offidani, MD, Laura Corvatta, MD, Monica Marconi, MD, Giuseppe Visani, MD, Francesco Alesiani, MD, Marino Brunori, MD, Piero Galieni, MD, Massimo Catarini, MD, Maurizio Burattini, MD, Riccardo Centurioni, MD, Serena Rupoli, MD, Anna Rita Scortechini, MD, Luciano Giuliodori, MD, Marco Candela, MD, Debora Capelli, MD, Mauro Montanari, MD, Attilio Olivieri, Ph. D., Maria-Novella Piersantelli, MD, Pietro Leoni, Ph. D.

Blood (2005) 106 (11): 2558.

https://doi.org/10.1182/blood.V106.11.2558.2558

Published: 2005

Journal Articles

Comparison of Two Regimens for the Treatment of Elderly Patients with Acute Lymphoblastic Leukaemia (ALL).

Massimo Offidani, MD, Laura Corvatta, MD, Lara Malerba, MD, Monica Marconi, MD, Massimo Catarini, MD, Riccardo Centurioni, MD, Franco Leoni, MD, Anna Rita Scortechini, MD, Maria Cristiana Masia, MD, Pietro Leoni, MD

Blood (2004) 104 (11): 4490.

https://doi.org/10.1182/blood.V104.11.4490.4490

Published: 2004

Journal Articles

High Dose Chemotherapy (HD CHT) Followed by Autologous PBPC Transplant in Elderly ANLL Patients.

Debora Capelli, MD, Emanuela Troiani, MD, Giancarlo Discepoli, MD, Antonella Poloni, MD, Mauro Montanari, MD, Massimo Catarini, MD, Riccardo Centurioni, MD, Francesco Alesiani, MD, Marino Brunori, MD, Moira Lucesole, MD, Pietro Leoni, MD, Attilio Olivieri, MD

Blood (2004) 104 (11): 881.

https://doi.org/10.1182/blood.V104.11.881.881

Published: 2004

NARROW

Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome

High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry

Assessment of Frailty Measures and Their Effect on Survival in a Population of Patients Registered At Marche Region Multiple Myeloma (MM) Registry

Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat In Patients with Relapsed/Refractory MM: a Phase I-II Study

Thalidomide, Dexamethasone, Doxil and Velcade (ThaDD-V) Induction Therapy Followed by Consolidation/Maintenance Is Very Effective In Early Relapsed/Refractory MM

MPT Vs ThaDD in Very Elderly Patients with Multiple Myeloma: a Case-Match Study.

Multicentric prospective Study of Differential Treatment for Elderly Patients Affected by Aggressive Non Hodgkin Lymphoma Based On a Geriatric Multidimensional Analysis.

Infection Complications in Patients with Multiple Myeloma Treated with New-Drug Combinations Including Thalidomide.

ThaDD Regimen for Patients with Multiple Myeloma Aged ≥ 65 Years: An Update of the First 50 Patients Enrolled

Role of Previous Thalidomide Administration on Final Outcome for 72 Patients with Relapsed Multiple Myeloma (MM) Treated with Bortezomib–Based Therapy

Safety and Efficacy of ThaDD Regimen in Very Elderly Patients with Multiple Myeloma (MM)

R-COMP 21 (Prednisone, Cyclophosphamide, Vincristine, Myocet tm and Rituximab) for Frail and Elderly Patients with Aggressive B-Cell Non-Hodgkin Lymphoma: A Pilot Study.

ThaDD-V Treatment for Patients with Relapsed/Refractory Multiple Myeloma: A Feasibility/Activity Study.

Thalidomide-Dexamethasone vs Interferon-α-Dexamethasone as Maintenance Treatment after ThaDD Induction for Multiple Myeloma (MM): Final Analysis of a Prospective, Randomized Study.

Thalidomide-Dexamethasone (Thal-dex) vs Interferon-α-Dexamethasone (IFN-dex) as Maintenance Treatment after ThaDD Induction for Multiple Myeloma (MM): First Analysis of a Prospective Randomized Study.

Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma

Thalidomide, Dexamethasone and Pegylated-Liposomal Doxorubicin (ThaDD) for Untreated Multiple Myeloma Patients Aged over 65 Years.

Comparison of Two Regimens for the Treatment of Elderly Patients with Acute Lymphoblastic Leukaemia (ALL).

High Dose Chemotherapy (HD CHT) Followed by Autologous PBPC Transplant in Elderly ANLL Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only